Rituximab works by binding to the CD20 antigen on B-cells. This binding prompts the immune system to attack and destroy these cells. The destruction of B-cells helps in reducing the proliferation of cancer cells, particularly in conditions like Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.
